“Association between contemporary hormonal contraception and ovarian cancer… “ https://www.bmj.com/content/362/bmj.k3609 “Previous research has shown a reduced risk of ovarian cancer in users of combined oral contraceptives, an effect that persists for many years after stopping use. Changes have occurred in formulations of combined oral contraceptives (notably reductions in oestrogen dose and the introduction of newer progestogens). It is important for users of contemporary combined oral contraceptives to know whether they are likely to experience the same pattern of ovarian cancer benefit as users in the older studies. The Danish Sex Hormone Register Study follows a national cohort of women aged 15-79 years. It was established to investigate the relation between hormone use and the risk of cancer or cardiovascular disease. We calculated age standardised incidence rates of ovarian cancers per 100 000 person years, using the age distribution of the cohort as...

World Ovarian Coalition   This information comes from: -                  https://www.eurekalert.org/pub_releases/2018-10/wocc-doo101518.php "The World Ovarian Cancer Coalition Every Woman Study is the largest ever review of the experiences of women with ovarian cancer and includes contributions from the clinical community. It presents a bleak picture of the challenges faced by women with ovarian cancer, and those who care for them. Nine in ten of the women in the Every Woman Study experienced symptoms prior to diagnosis and of these, eight in ten consulted a doctor - though less than half within a month and one in ten waited six months. Across the world, diagnosis took an estimated average of 31 weeks from a woman experiencing symptoms to her diagnosis; for one in ten women diagnosis came more than a year after visiting a doctor. A survey participant in Australia said "Governments need to do more regarding G...

“Familial risks of ovarian cancer….” This information comes from:-        https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0205000 “Ovarian cancer risk increases with aging and peaks between the ages of 50 and 80 years. In the general Swedish population, the lifetime risk of ovarian cancer is 1%.  Family history is a strong risk factor for ovarian cancer, and the relative risk is estimated to be 2.0 to 4.0 for those that have a first-degree relative affected by the disease In this study, we use the recent national Swedish Family-Cancer Database, which included 16.1 million individuals, to estimate the familial risks of ovarian cancer by age at diagnosis, affected relative (mother or sisters) and histology. In families of only mother, only sisters or both mother and sisters diagnosed with ovarian cancer, cancer risks for ovary were 2.40, 2.59 and 10.40, respectively; and were higher for cases diagnosed before the age of...

This information comes from:- https://today.uic.edu/crosstalk-between-fallopian-tube-ovary-may-drive-the-spread-of-ovarian-cancer- - https://www.cancer.gov/news-events/cancer-currents-blog/2017/ovarian-cancer-fallopian-tube-origins "Over the last several years we have come to learn that ovarian cancer cells, specifically high-grade serous ovarian cancer cells, originate in the fallopian tube and migrate to the ovary where they become established as ovarian cancer.  We don’t know yet what the fallopian tube signals to the ovary, but we know that it causes the ovary to release norepinephrine, which signals cancer cells to migrate. - There is a window of several years between the development of abnormal cells, or lesions, in the fallopian tubes and the start of ovarian cancer Most of the genetic alterations seen in ovarian tumors in these patients were present in serous tubal intraepithelial carcinomas (STICs) that had formed years earlier in their fallopi...

"Poly (ADP-ribose) Polymerase Inhibitors (PARPi)  in the Management of Ovarian Cancer"   This information comes from https://www.ptcommunity.com/journal/article/full/2018/9/549/poly-adp-ribose-polymerase-inhibitors-management-ovarian-cancer-drug - https://www.eurekalert.org/pub_releases/2018-09/waeh-dpw092618.php "Familial and hereditary factors have been identified in the development of some cases of ovarian cancer, with approximately 10% to 15% of ovarian cancer cases associated with inherited mutations of the BRCA1 and BRCA2 genes. Upon recurrence of disease, the goal of treatment is no longer curative, but instead becomes palliative, aimed at improving disease-related symptoms, prolonging survival, and trying to improve quality of life. For patients harbouring a BRCA1/2 mutation, medications targeting PARP enzymes may be an effective therapeutic option. PARP is a family of enzymes that mediate DNA repair... PARP inhibition in the settin...